ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Tumor buster-where will the CAR-T cell therapy 'missile' go?

Qu, Chunrun; Zhang, Hao; Cao, Hui; Tang, Lanhua; Mo, Haoyang; Liu, Fangkun; Zhang, Liyang; Yi, Zhenjie; Long, Lifu; Yan, Luzhe; Wang, Zeyu; Zhang, Nan; Luo, Peng; Zhang, Jian; Liu, Zaoqu; Ye, Weijie; Liu, Zhixiong*; Cheng, Quan*南方医科大学; 哈尔滨医科大学
Molecular Cancer2022-10-19DOI: 10.1186/s12943-022-01669-8
24被引5阅读
引用收藏
分享

摘要

Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing technology represents a significant breakthrough in personalized immunotherapy for human cancer. This strategy uses genetic modification to enable T cells to target tumor-specific antigens, attack specific cancer cells, and bypass tumor cell apoptosis avoidance mechanisms to some extent. This method has been extensively used to treat hematologic diseases, but the therapeutic effect in solid tumors is not ideal. Tumor antigen escape, treatment-related toxicity, and the immunosuppressive tumor microenvironment (TME) limit their use of it. Target selection is the most critical aspect in determining the prognosis of patients receiving this treatment. This review provides a comprehensive summary of all therapeutic targets used in the clinic or shown promising potential. We summarize CAR-T cell therapies' clinical trials, applications, research frontiers, and limitations in treating different cancers. We also explore coping strategies when encountering sub-optimal tumor-associated antigens (TAA) or TAA loss. Moreover, the importance of CAR-T cell therapy in cancer immunotherapy is emphasized.

学科与关键词

关键词
CAR-T cellImmunotherapyTargetCancerPersonalized treatment
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Molecular Cancer
发表日期
2022-10-19
卷期
第 21 卷, 第 1 期
页码
201
DOI
10.1186/s12943-022-01669-8
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82073893, 82172685, 81873635, 81703622]; Hunan Provincial Natural Science Foundation of China [2022JJ20095, 2018SK2101, 2018JJ3838]; China Postdoctoral Science Foundation [2018 M633002]; Hunan Provincial Health Committee Foundation of China [202204044869]; Xiangya Hospital Central South University postdoctoral foundation

作者

  • Q

    Qu, Chunrun (第一作者)

  • Z

    Zhang, Hao

    2 · chongqing med univ

查看全部 18 位作者收起作者
  • C

    Cao, Hui

    2 · hunan univ chinese med · peoples hosp hunan prov

  • T

    Tang, Lanhua

  • M

    Mo, Haoyang

  • L

    Liu, Fangkun

  • Z

    Zhang, Liyang

  • Y

    Yi, Zhenjie

  • L

    Long, Lifu

  • Y

    Yan, Luzhe

  • W

    Wang, Zeyu

  • Z

    Zhang, Nan

    harbin med univ

  • L

    Luo, Peng

    southern med univ

  • Z

    Zhang, Jian

    southern med univ

  • L

    Liu, Zaoqu

  • Y

    Ye, Weijie

  • L

    Liu, Zhixiong (通讯)

  • C

    Cheng, Quan (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417